Lobular neoplasia occult on conventional imaging and diagnosed on MRI-guided biopsy: can we estimate upgrade on surgical pathology?


Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 26 06 2020
accepted: 18 08 2020
pubmed: 6 9 2020
medline: 24 6 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

The goal of this study is to evaluate the frequency and imaging features of lobular neoplasia (LN) diagnosed on MRI-guided biopsy, determine the upgrade rate to malignancy, and assess for any features that may be associated with an upgrade on surgical excision. Research ethical board approved the review of consecutive patients with MRI-detected LN between January 2009 and December 2018 with differentiation between pure LN and LN with associated other high-risk lesions. The final outcome was determined by final pathology results from surgical excision or 24 months of follow-up. Appropriate statistical tests were used. Out of 1250 MRI-guided biopsies performed, 76 lesions (6%) fulfilled the inclusion criteria and formed the study cohort. Of the 76 lesions, 54 (71%) were pure LN while the rest had coexistent high-risk lesion. Non-mass enhancement (NME) was the most common lesion type (62, 82%). Fifty-nine lesions (78%) were surgically excised, the other 17 had benign follow-up. Overall, 8 lesions (11%) were upgraded to malignancy on final pathology. Malignant outcome was associated with larger lesion size (5.5 versus 1.9 cm, P < 0.001) and a clumped NME pattern (75% versus 24%, P = 0.006). Lesion size and clumped NME remained significantly associated with upgrade on sub-analysis of the pure LN group. Larger lesion size and clumped NME are imaging findings associated with upgrade of LN diagnosed by MRI-guided biopsy. This may influence patient management in this clinical setting. Additional larger studies are needed to consolidate our results and to potentially detect additional factors associated with upgrade.

Identifiants

pubmed: 32888139
doi: 10.1007/s10549-020-05893-y
pii: 10.1007/s10549-020-05893-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

881-890

Auteurs

Yoav Amitai (Y)

Joint Department of Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

Tehillah S Menes (TS)

Department of Surgery, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, 6 Weizmann St., 64239, Tel Aviv, Israel.

Anabel Scaranelo (A)

Joint Department of Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

Rachel Fleming (R)

Joint Department of Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

Supriya Kulkarni (S)

Joint Department of Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

Sandeep Ghai (S)

Joint Department of Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

Tulin Cil (T)

University Health Network, Department of Surgical Oncology, University of Toronto, 3-130, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.

Susan Done (S)

Laboratory Medicine Program, University Health Network, Toronto General Hospital Site, University of Toronto, 200 Elizabeth Street, 11th Floor Eaton Wing, Toronto, ON, M5G 2C4, Canada.

Vivianne Freitas (V)

Joint Department of Medical Imaging, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. vivianne.freitas@uhn.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH